MedTrace Logo

Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients

NCT02111031 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-06-19

No results posted yet for this study

Summary

The objective of the registry study is to demonstrate the clinical utility of the CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in the United States. The objective of the present registry is to demonstrate the impact on patient management of the CELLSEARCH® CTC Test among the Medicare-eligible mBC patients. Hereto the hypothesis that the availability of CTC information provides clinicians important, timely information and impacts treatment decisions, will be tested.

This study is IDE-exempt since CELLSEARCH® CTC Test is a legally marketed device in the US, and is being used in accordance with its labeling.

Conditions

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • Janssen Diagnostics, LLC

    lead INDUSTRY

Principal Investigators

  • Alberto Montero, MD · Cleveland Clinic Main Campus

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02111031 on ClinicalTrials.gov